Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

34.180
-1.120-3.17%
Volume:11.38M
Turnover:393.65M
Market Cap:207.27B
PE:31.41
High:34.660
Open:34.480
Low:33.640
Close:35.300
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:3.18
T/O Rate:0.19%
Dividend:0.50
Dividend Rate:1.45%
EPS(LYR):1.088
ROE:19.40%
ROA:9.08%
PB:4.69
PE(LYR):31.41
PS:11.14

Loading ...

Hansoh Pharmaceutical Group Stock Climbs 2.2% in Hong Kong

Dow Jones
·
Sep 02

Hansoh Pharmaceutical Says NMPA Accepts Biologics License Application of HS-20093

Reuters
·
Sep 02

CLSA Lifts Hansoh Pharma Target Price to HK$43.70, Reaffirms Outperform Rating

Deep News
·
Sep 01

Movement Alert|HANSOH PHARMA Declines 3.28% in Regular Trading, Post-Earnings Profit-Taking Extends Amid Pharma Sector Weakness

Market Focus
·
Sep 01

JPMorgan Reaffirms 'Overweight' on Hansoh Pharma, Lifts Target Price to HK$50

Stock News
·
Aug 31

Hansoh Pharmaceutical Group Stock Sheds 3.8% in Hong Kong

Dow Jones
·
Aug 31

Movement Alert|HANSOH PHARMA Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Meets Broad Pharma Sector Weakness

Market Focus
·
Aug 31

Here's What Analysts Are Forecasting For Hansoh Pharmaceutical Group Company Limited (HKG:3692) After Its Half-Year Results

Simply Wall St.
·
Aug 29

China's Zhaoke Ophthalmology H1 Revenue Rises

Reuters
·
Aug 28

China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales

Reuters
·
Aug 27

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Reuters
·
Aug 27

Goldman Sachs Boosts HANSOH PHARMA Price Target on Strong First-Half Results

Stock News
·
Aug 27

Why Hansoh Pharma Surged Over 16% After Its Earnings Report?

Deep News
·
Aug 27

Biocytogen Pharmaceuticals H1 Revenue up 51.6%

Reuters
·
Aug 27

Hansoh Pharmaceutical Group Stock Advances 16% in Hong Kong

Dow Jones
·
Aug 27

China's Hansoh Pharmaceutical Jumps Most on Record on H1 Profit Growth

Reuters
·
Aug 27

Movement Alert|HANSOH PHARMA Rises 5.73% in Regular Trading, H1 Net Profit Surges 35.8% Year-over-Year

Market Focus
·
Aug 27

Stronger Half Year Earnings And Profitability Could Be A Game Changer For Hansoh (SEHK:3692)

Simply Wall St.
·
Aug 26

Grand Pharmaceutical H1 Revenue Rises on Nuclear Medicine Demand

Reuters
·
Aug 26

HANSOH PHARMA lowers CB conversion price to HK$56.54, potential share issuance up 1.5%

Bulletin Express
·
Aug 26